Mizuho's Positive Outlook on Amgen's Innovative Pipeline and Market Prospects
ByBola Sokunbi
This article examines Mizuho's updated analysis of Amgen Inc. (NASDAQ: AMGN), focusing on the pharmaceutical giant's promising drug pipeline, particularly MariTide and olpasiran. It delves into Mizuho's rationale for increasing its price target and highlights key catalysts and potential challenges for Amgen in the coming years.
Mizuho Elevates Amgen's Price Target Amidst Promising Drug Developments
Mizuho has revised its price target for Amgen Inc. (NASDAQ: AMGN) upwards to $303 from $295, while maintaining a 'Neutral' rating. This adjustment reflects the firm's confidence in Amgen's robust pipeline, with particular emphasis on the therapeutic potential of MariTide and olpasiran.
The Strategic Impact of Lp(a) Research on Amgen's Market Position
Mizuho highlighted that the anticipated completion of Novartis and Ionis Pharmaceuticals' Phase 3 Lp(a) research in early 2026 could significantly benefit Amgen Inc. (NASDAQ: AMGN). The outcome of this research is expected to reshape market perceptions and valuations within the cardiovascular therapeutics space.
Anticipated Market Shift: Olpasiran Takes Center Stage
Following a slight increase in Amgen Inc.'s (NASDAQ: AMGN) medium-term sales projections, Mizuho foresees a shift in investor focus towards olpasiran. This heightened attention is expected once data from the Novartis and Ionis Phase 3 Lp(a) research becomes available, likely in the first half of 2026. The release of olpasiran's own clinical data is expected to follow later.
Despite the positive pipeline outlook, Mizuho acknowledged a potential risk stemming from a tax dispute with the IRS. The firm noted that a resolution is not expected before the latter half of 2026, and further details regarding this matter are being sought to assess its full impact on Amgen Inc. (NASDAQ: AMGN).
Amgen's Core Business: A Leader in Pharmaceutical Innovation
Amgen Inc. (NASDAQ: AMGN), established in 1980 and headquartered in California, stands as a prominent drug manufacturer. The company is dedicated to delivering human therapeutics through established pharmaceutical wholesale distribution channels, reinforcing its role as a key player in the biotechnology sector.
About the author
Bola Sokunbi
Founder of Clever Girl Finance, providing financial education geared toward women of color.
